Serum levels of interleukin 6 in patients with lung cancer

Yanagawa, Hiroaki; Sone, Saburo; Takahashi, Yûji; Haku, Takashi; Yano, Saburo; Shinohara, Toshihiko; Ogura, Takeshi

doi:10.1038/bjc.1995.212

Cited by 156 publications

(115 citation statements)

References 29 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Indeed, there is evidence that proinflammatory cytokines are produced locally by tumours in patients with NSCLC (Arias-Diaz et al, 1994). In particular, interleukin-6 is recognised as a primary mediator of increased C-reactive protein concentrations in these patients (Yanagawa et al, 1995;Scott et al, 1996). However, whether interleukin-6 is produced directly by lung cancer cells remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer

et al. 2003

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer

et al. 2003

View full text Add to dashboard Cite

show abstract

“…There is some evidence that proinflammatory cytokines, especially IL-6, act as endogenous pyogens (Gauldie et al, 1987;Castel et al, 1990) and mediate experimental cachexia from cancer (Strassmann et al, 1992). IL-6 affects systemic nutrition and metabolism and is responsible for many of the clinically observed nutritional effects of injury, infection and cancer (Souba, 1994;Yanagawa et al, 1995;Oka et al, 1996). As a significant correlation was found between the serum concentration of HGF and IL-6 in the present study, our findings suggest that serum HGF may be a possible index that reflects tumour-induced malnutrition developed in the patients with advanced colorectal carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma

Fukuura

Miki²,

Inoue³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary To evaluate the clinical significance of serum levels of hepatocyte growth factor (HGF) in colorectal cancer patients, we measured the venous and portal concentrations of HGF in 60 patients. The tissue concentrations in the tumour and adjacent normal mucosa were also determined. The serum HGF concentration for the peripheral venous blood of the patients was significantly higher than that in normal controls. The content of HGF in cancer tissue was also significantly higher than that in normal mucosa, and it was correlated with the serum HGF concentration for the peripheral venous blood. The serum concentration of HGF reflected pathological features, including tumour size and lymph node or liver metastasis, and it showed an association with various preoperative nutritional parameters and the preoperative haemoglobin level. The serum HGF concentration was also correlated with the serum concentrations of immunosuppressive acidic protein and interleukin-6, indices of the host's immunological condition. Serum HGF seems to be a useful index of the disease status of patients with colorectal carcinoma.Keywords: hepatocyte growth factor; nutritional status; immunological status; colorectal cancer Hepatocyte growth factor (HGF) is a multifunctional cytokine that is the most potent known stimulator of hepatocyte growth and DNA synthesis Kaneko et al, 1992). HGF has also been recognized as a tumour-disseminating factor (Weidner et al, 1991;Mayer et al, 1993;Tannapfel et al, 1994). In several experimental studies, evidence has been acquired of a relation of HGF to the progression of tumour cells . Among the particularly important biological activities of HGF in tumour cells is its capacity to increase epithelial cell proliferation and motility (Gherardi et al, 1990). In clinical studies, a relationship between the concentration of HGF in serum or cancer tissue and the progression of disease has been noted in patients with gastric cancer (Taniguchi et al, 1997), oesophageal cancer (Takada et al, 1995) and breast cancer (Yamashita et al, 1994;Taniguchi et al, 1995). However, there are no reports regarding the clinical relevance of HGF in patients with colorectal carcinoma.Malnutrition or immunosuppression are involved in the development of life-threatening complications in patients with malignancies (Braga et al, 1988;Nishi et al, 1988;Dannhauser et al, 1995;Triantafillidis et al, 1995;Windsor et al, 1995;Goransson et al, 1996). Patients with advanced cancer and cachexia typically demonstrate modestly increased rates of energy expenditure with concomitant diminished food intake. These metabolic changes may be due to mediators released by the tumour or by the host (Keller, 1993). Recently, the role of cytokines in these metabolic changes was emphasized (Gambardella et al, 1997). In addition, the relationship between cytokines and an immunosuppressive substance has also been highlighted (Tanaka et al, 1993 The objective of this study was to evaluate the relationship between serum HGF concentration and clinicopathological ...

show abstract

“…Indeed, in humans interleukin 6 appears to be a primary regulator of the acute phase response (Heinrich et al, 1990). Furthermore, reports have documented an increase in circulating interleukin 6 concentrations in gastrointestinal cancer (Fearon et al, 1991;Falconer et al, 1994b) and lung cancer patients (Yanagawa et al, 1995).…”

mentioning

confidence: 96%

The relationship between weight loss and interleukin 6 in non-small-cell lung cancer

Scott

McMillan²,

Crilly³

et al. 1996

Br J Cancer

165

View full text Add to dashboard Cite

SmaryMarkers of the inflammatory response, interleukin 6, C-reactive protein, albumin and full blood count, were measured in non-small-cell lung cancer (NSCLC) patients (n=21) with and without weight loss (>5%). There were significant increases in circulating C-reactive protein (P<0.001), interleukin 6 (P<0.01) and platelets (P<0.01) in the weight-losing group. Moreover, there was a statistically significnt correlation (r=0.785, P<0.001) between interleukin 6 and C-reactive protein concentrations. These results are consistent with interleukin 6 and the acute phase response promoting weight loss in NSCLC.

show abstract

Serum levels of interleukin 6 in patients with lung cancer

Cited by 156 publications

References 29 publications

Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer

Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer

Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma

The relationship between weight loss and interleukin 6 in non-small-cell lung cancer

Contact Info

Product

Resources

About